View Author
patient myeloma treatment study thalidomide therapy response blood bortezomib month survival lenalidomide trial group dexamethasone cycle transplantation analysis grade cell transplantation relapse chromosome melphalan phase result signi neuropathy effect disease table induction factor regimen autologou combination cancer high-dose abnormality mirna maintenance randomized myeloma patients ef ficacy number response rate expression prognostic signi ficantly marrow hovon chemotherapy department erasmus mc outcome cytogenetic agent center prednisone toxicity value allogeneic figure deletion level novel myeloablative hospital protocol university hematology leukemia novel agents allo-sct netherland randomization donor-derived bm mscs /refractory progression cyclophosphamide stage
10 Most Recent Publications
|
Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
(Article)
Neben, K. Lokhorst, H.M. Scheid, C. Dührsen, U. Lindemann, W. Schmidt-Wolf, I.G.H. Peter, N. Teschendorf, C. Martin, H. Haenel, M. Derigs, H.G. Raab, M.S. Jauch, A. Ho, A.D. Velde, C.J.H. van de Hose, D. Sonneveld, P. Goldschmidt, H. Bertsch, U. Hielscher, T. Holt, B.D. van Salwender, H. Blau, I.W. Weisel, K. Pfreundschuh, M. |
2012-01-26
|
|
MicroRNA signatures characterize multiple myeloma patients
(Article)
Corthals, S.L. Sun, S.M. Zweegman, S. Jongen-Lavrencic, M. Sonneveld, P. Kuiper, R. Knegt, Y. de Broyl, A. Holt, B. van der Beverloo, H.B. Peeters, J.K. Jarari, L. Lokhorst, H.M. |
2011-11-01
|
|
Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)
(Article)
Palumbo, A. Bringhen, S. Zweegman, S. Terpos, E. Davies, F. Driessen, C. Gimsing, P. Gramatzki, M. Hajek, R. Johnsen, H.E. Da Costa, F.L. Sezer, O. Ludwig, H. Spencer, A. Beksaç, M. Morgan, G. Einsele, H. San Miguel, J. Sonneveld, P. Dimopoulos, M.A. Bladé, J. Mateos, M.V. Rosiñol, L. Boccadoro, M. Cavo, M. Lokhorst, H.M. |
2011-10-27
|
|
Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: Results of the HOVON 76 Trial
(Article)
Kneppers, E. Holt, B. van der Bruijnen, C.P. Emmelot, M. Sonneveld, P. Lokhorst, H.M. Mutis, T. Minnema, M.C. Kersten, M.J. Zweegman, S. Meijer, E. Huls, G. Cornelissen, J.J. Janssen, J.J. Huisman, C. Cornelisse, P.B. |
2011-09-01
|
|
Treatment of relapsed and refractory multiple myeloma in the era of novel agents
(Article)
Donk, N.W.C.J. van de Lokhorst, H.M. Goldschmidt, H. Sonneveld, P. Johnsen, H.E. Bladé, J. San-Miguel, J-F. Palumbo, A. Dimopoulos, M.A. Cavo, M. Morgan, G. Einsele, H. Kropff, M. Schey, S. Avet-Loiseau, H. Ludwig, H. |
2011-06-01
|
|
Effect of thalidomide with melphalan and prednisone on health-related quality of life (HRQoL) in elderly patients with newly diagnosed multiple myeloma: a prospective analysis in a randomized trial
(Article)
Verelst, S.G.R. Termorshuizen, F. Lokhorst, H.M. Sonneveld, P. Wijermans, P. Uyl-de Groot, C.A. Schaafsma, M.R. Ammerlaan, A.H.M. Wittebol, S. Sinnige, H.A.M. Zweegman, S. Marwijk Kooy, M. van Griend, R. van der |
2011-04-07
|
|
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial
(Article)
Broyl, A. Corthals, S.L. Durie, M.G. Goldschmidt, H. Sonneveld, P. Jongen, J.L.M. Holt, B. van der Kuiper, R. Knegt, Y. de Duin, M. van Jarari, L. Bertsch, U. Lokhorst, H.M. |
2010-11-01
|
|
European Myeloma Network: The 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma
(Article)
Engelhardt, M. Udi, J. Driessen, C. Patriarca, F. Gramatzki, M. Terpos, E. Sezer, O. Kropff, M. Straka, C. Johnsen, H.E. Waage, A. Boegsted, M. Kleber, M. Lokhorst, H.M. Hjek, R. Morgan, G. Boccadoro, M. Ludwig, H. Cavo, M. Polliack, A. Sonneveld, P. Einsele, H. Palumbo, A. Spencer, A. Rocci, A. Knop, S. Bruno, B. Bringhen, S. Pérez-Simn, J.A. Zweegman, S. |
2010-11-01
|
|
Micro-RNA-15a and micro-RNA-16 expression and chromosome 13 deletions in multiple myeloma
(Article)
Corthals, S.L. Jongen-Lavrencic, M. Knegt, Y. de Peeters, J. Beverloo, H.B. Lokhorst, H.M. Sonneveld, P. |
2010-05-01
|
|
A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
(Article)
Lokhorst, H.M. Holt, B. van der Wittebol, S. Delforge, M. Berenschot, H. Bos, G.M. Jie, K.S-G. Sinnige, H. Marwijk Kooy, M. van Joosten, P. Minnema, M.C. Ammerlaan, R. van Zweegman, S. Sonneveld, P. Vellenga, E. Croockewit, S. Oers, M.H.J. van von dem Borne, P.A. Wijermans, P.W. Schaafsma, R. de Weerdt, O. |
2010-02-11
|
